Synthesis and antitumor activity of 2,5-bis(3′-indolyl)-furans and 3,5-bis(3′-indolyl)-isoxazoles, nortopsentin analogues

Bioorganic and Medicinal Chemistry

Volumn 18, Issue 12, 2010, Pages 4524-4529

  Diana, Patrizia ^a   Carbone, Anna ^a   Barraja, Paola ^a   Kelter, Gerhard ^b   Fiebig, Heinz Herbert ^b   Cirrincione, Girolamo ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

2,5 Bis(3 indolyl)furans; 3,5 Bis(3 indolyl)isoxazoles; Antitumor activity; Nortopsentin

Indexed keywords

2,5 BIS(3' INDOLYL)FURAN DERIVATIVE; 3 3' FURAN 2,5 DIYLBIS(1 METHYL 1H INDOLE); 3 3' FURAN 2,5 DIYLBIS(5 METHOXY 1 METHYL 1H INDOLE); 3 3' ISOXAZOLE 3,5 DIYLBIS(1 METHYL 1H INDOLE); 3 3' ISOXAZOLE 3,5 DIYLBIS(5 METHOXY 1 METHYL 1H INDOLE); 3,5 BIS(3' INDOLYL)ISOXAZOLE DERIVATIVE; ANTINEOPLASTIC AGENT; DOXORUBICIN; FURAN DERIVATIVE; ISOXAZOLE DERIVATIVE; NORTOPSENTIN ANALOGUE; UNCLASSIFIED DRUG; 3-3'-FURAN-2,5-DIYLBIS(1-METHYL-1H-INDOLE); 3-3'-ISOXAZOLE-3,5-DIYLBIS(5-METHOXY-1-METHYL-1H-INDOLE); INDOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOUSE; NONHUMAN; CHEMISTRY; NEOPLASMS; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FURANS; HUMANS; INDOLES; ISOXAZOLES; NEOPLASMS;

EID: 77953129279     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2010.04.061     Document Type: Article

References (24)

1. Shin J., Seo Y., Cho K.W., Rho J.R., and Sim C.J. J. Nat. Prod. 62 (1999) 647
2. Casapullo A., Bifulco G., Bruno I., and Riccio R. J. Nat. Prod. 63 (2000) 447
3. Bao B., Sun Q., Yao X., Hong J., Lee C., Sim C.J., and Jung J.H. J. Nat. Prod. 68 (2005) 711
4. Gul W., and Hamann M.T. Life Sci. 78 (2005) 442
5. Alvarez M., and Salas M. Heterocycles 32 (1991) 1391
6. Sakem S., and Sun H.H. J. Org. Chem. 56 (1991) 4304
7. Kawasaki I., Yamashita M., and Ohta S. Chem. Pharm. Bull. 44 (1996) 1831
8. Gu X., Wan X., and Jiang B. Bioorg. Med. Chem. Lett. 9 (1999) 569
9. Jiang B., and Gu X. Bioorg. Med. Chem. Lett. 8 (2000) 363
10. Jiang B., Xiong X., and Yang C. Bioorg. Med. Chem. 9 (2001) 1149
11. Jiang B., Xiong X., and Yang C. Bioorg. Med. Chem. Lett. 11 (2001) 475
12. Xiong W., Yang C., and Jiang B. Bioorg. Med. Chem. 9 (2001) 1773
13. Diana P., Carbone A., Barraja P., Montalbano A., Martorana A., Dattolo G., Gia O., Dalla Via L., and Cirrincione G. Bioorg. Med. Chem. Lett. 17 (2007) 2342
14. Diana P., Carbone A., Barraja P., Martorana A., Dattolo G., Gia O., Dalla Via L., and Cirrincione G. Bioorg. Med. Chem. Lett. 17 (2007) 6134
15. Bey E., Marchais-Oberwinkler S., Kruchten P., Frotscher M., Werth R., Oster A., Algül O., Neugebauer A., and Hartmann R.W. Bioorg. Med. Chem. 16 (2008) 6423
16. Garattini E., Parella E., Diomede L., Giannì M., Kalac Y., Merlini L., Simoni D., Zanier R., Ferrara F.F., Chiarucci I., Carminati P., Terao M., and Pisano C. Blood 103 (2004) 194
17. Sun C., Lin L., Yu H., Cheng C., Tsai Y., Chu C., Din Y., Chau Y., and Don M. Bioorg. Med. Chem. Lett. 17 (2007) 1078
18. Kaffy J., Pontikis R., Carrez D., Croisy A., Monneret C., and Florent J. Bioorg. Med. Chem. 14 (2006) 4067
19. de Olivera R.B., de Souza-Fagundes E.M., Siqueira H.A.J., Leite R.S., Donnici C.L., and Zani C.L. Eur. J. Med. Chem. 41 (2006) 756
20. Simoni D., Rondanin R., Baruchello R., Rizzi M., Grisolia G., Eleopra M., Grimaudo S., Di Cristina A., Pipitone M.R., Bongiorno M.R., Aricò M., Invidiata F.P., and Tolomeo M. J. Med. Chem. 51 (2008) 4796
21. Dengler W.A., Schulte J., Berger D.P., Mertelsmann R., and Fiebig H.H. Anti-Cancer Drugs 6 (1995) 522
22. Roth T., Burger A.M., Dengler W., Willmann H., and Fiebig H.H. Contrib. Oncol. 54 (1999) 145
23. Fiebig H.H., Dengler W.A., and Roth T. Contrib. Oncol. 54 (1999) 29
24. Fiebig H.H., Berger D.P., Dengler W.A., Wallbrecher E., and Winterhalter B.R. Contrib. Oncol. 42 (1992) 321